Lubbertus C. Baak - Publications

Comparative performance of HCC risk scores in identifying low-risk patients with cirrhosis: A multicenter cohort study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: May 19, 2026

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.

Journal: Alimentary pharmacology & therapeutics

Published: November 13, 2025

Rifaximin-α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization.

Journal: United European gastroenterology journal

Published: September 05, 2024

Incidence and prevalence of primary biliary cholangitis in the Netherlands - A nationwide cohort study.

Journal: JHEP reports : innovation in hepatology

Published: February 09, 2024

Decompensation as initial presentation in patients with liver cirrhosis is associated with an increased risk of future decompensation and mortality.

Journal: Scandinavian journal of gastroenterology

Published: February 10, 2023

Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: January 19, 2021

Liver stiffness improvement in hepatitis C patients after successful treatment.

Journal: The Netherlands journal of medicine

Published: December 31, 2020

Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial.

Journal: Trials

Published: January 02, 2018

Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus.

Journal: Nature communications

Published: February 03, 2016

Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.

Journal: Journal of viral hepatitis

Published: February 03, 2016

Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.

Journal: Gut

Published: March 23, 2015

Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.

Journal: The Netherlands journal of medicine

Published: November 13, 2014